Literature DB >> 8627511

Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.

M Nakajima1, T Yamamoto, K Nunoya, T Yokoi, K Nagashima, K Inoue, Y Funae, N Shimada, T Kamataki, Y Kuroiwa.   

Abstract

Nicotine is primarily metabolized to cotinine, and cotinine is further metabolized to trans-3'-hydroxycotinine in human liver, which is a major metabolite of nicotine in humans. We studied the formation of trans-3'-hydroxycotinine from cotinine in human liver microsomes. trans-3'-Hydroxycotinine formation demonstrated single enzyme Michaelis-Menten kinetics (Km, 234.5 +/- 26.8 MicroM; Vmax, 37.2 +/- 2.4 pmol/min/mg protein). Significant correlation (r = .967, P < .001) between cotinine 3'-hydroxylase activities at low (50 microM) and high (1 microM) cotinine concentrations in 20 human liver microsomes suggested the contribution of a single enzyme to cotinine 3'-hydroxylation. The cotinine 3'-hydroxylase activity correlated significantly with immunoreactive cytochrome P450 (CYP)2A6 contents (r = .756, P < .01) and coumarin 7-hydroxylase activity (r = .887, P < .001). The cotinine 3'-hydroxylase activity was inhibited by coumarin, alpha-naphthoflavone, chlorzoxazone and anti-rat CYP2A1 antibodies. Microsomes of B-lymphoblastoid cells expressing human CYP2A6 exhibited cotinine 3'-hydroxylase activity. The Km value of the expressed CYP2A6 (264.7 microM) was almost identical to that of human liver microsomes. In conclusion, cotinine 3'-hydroxylation appears to be catalyzed solely by CYP2A6 in humans. Cotinine is a candidate for a new substrate for CYP2A6 in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627511

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  83 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 2.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

3.  Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population.

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Saori Kawauchi; Shoko Higuchi; Chie Ogawa; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

4.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 5.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

Review 6.  Pharmacogenetics and smoking cessation with nicotine replacement therapy.

Authors:  Riju Ray; Robert A Schnoll; Caryn Lerman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

8.  Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.

Authors:  Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox
Journal:  Addict Behav       Date:  2012-11-29       Impact factor: 3.913

9.  Utility and relationships of biomarkers of smoking in African-American light smokers.

Authors:  Man Ki Ho; Babalola Faseru; Won S Choi; Nicole L Nollen; Matthew S Mayo; Janet L Thomas; Kolawole S Okuyemi; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Authors:  Stephani L Stancil; Robin E Pearce; Rachel F Tyndale; Gregory L Kearns; Carrie A Vyhlidal; J Steven Leeder; Susan Abdel-Rahman
Journal:  Br J Clin Pharmacol       Date:  2019-03-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.